Navigation Links
CV Therapeutics Statement on Unsolicited Proposal From Astellas
Date:1/27/2009

PALO ALTO, Calif., Jan. 28 /PRNewswire-FirstCall/ -- In light of an announcement made recently by Astellas Pharma Inc., CV Therapeutics, Inc. (Nasdaq: CVTX) confirmed that it had received a letter dated November 13, 2008 from Astellas setting forth an unsolicited proposal by Astellas to acquire CV Therapeutics at a price of $16.00 per share, subject to due diligence, Astellas board approval and other conditions.

After careful deliberation, with the assistance of its financial and legal advisors, the CV Therapeutics board of directors had, on November 21, 2008, concluded that the Astellas proposal was not in the best interests of CV Therapeutics and its stockholders. Dr. Louis Lange, chairman and chief executive officer of CV Therapeutics, sent a letter dated November 21, 2008 to that effect to Astellas on behalf of the board of directors of CV Therapeutics.

Because Astellas, by its recent announcement, has sought to revive its previously rejected proposal, the CV Therapeutics board of directors will again review developments in the context of the company's strategic plans and the long-term interests of its stockholders, to pursue the best course of action to maximize long-term value for stockholders. As part of its ongoing review of the current market environment and the recent developments relating to CV Therapeutics, the board of CV Therapeutics concluded that it was in the best interests of CV Therapeutics and its stockholders to extend the expiration date of its shareholder rights plan from February 1, 2009 to February 1, 2010. CV Therapeutics will keep its stockholders advised.

Barclays Capital is serving as financial advisor, and Latham & Watkins LLP is serving as legal counsel, to CV Therapeutics.

About CV Therapeutics

CV Therapeutics, Inc., headquartered
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 Research and Markets ... Albumin Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... The report provides a basic overview of the ... The human albumin market analysis is provided for the ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... a FM-4910 listed material, to stay competitive in ... These high-performance materials ultimately impact product quality ... President and owner. , Established in 1980 in ... strong as many fabricators have left the business. ...
(Date:9/18/2014)...  MEI Pharma, Inc. (Nasdaq: MEIP ), an ... for cancer, announced today that Daniel P. Gold , ... NewsMakers in the Biotech Industry conference on Friday, ... Millennium Broadway Hotel & Conference Center in New ... be accessed at www.meipharma.com . A replay will be ...
(Date:9/18/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY ... but separate underwritten offerings of 10,000,000 shares of its ... $2.00 per share, for expected gross proceeds of $20 ... Preferred Stock at a price to the public of ... million. Each share of Series A Convertible Preferred Stock ...
Breaking Biology Technology:Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... NEW YORK, Sept. 8, 2011 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0611079/Global-D-Amino-Acids-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechno This ... Acids in US$ Million. The report provides ...
... Sept. 8, 2011 Reportlinker.com announces that a ... its catalogue: Global Metabolomics ... This report analyzes the worldwide ... report provides separate comprehensive analytics for the ...
... a single set of chromosomes for the first time ... The technique should allow scientists to better establish the ... usually contain two sets of chromosomes one set ... genetic information contained in these chromosome sets helps determine ...
Cached Biology Technology:Global D-Amino Acids Industry 2Global D-Amino Acids Industry 3Global D-Amino Acids Industry 4Global D-Amino Acids Industry 5Global D-Amino Acids Industry 6Global D-Amino Acids Industry 7Global D-Amino Acids Industry 8Global D-Amino Acids Industry 9Global D-Amino Acids Industry 10Global D-Amino Acids Industry 11Global D-Amino Acids Industry 12Global D-Amino Acids Industry 13Global D-Amino Acids Industry 14Global D-Amino Acids Industry 15Global D-Amino Acids Industry 16Global Metabolomics Industry 2Global Metabolomics Industry 3Global Metabolomics Industry 4Global Metabolomics Industry 5Global Metabolomics Industry 6Global Metabolomics Industry 7Scientists create mammalian cells with single chromosome set 2
(Date:9/18/2014)... researchers from McGill University and the Quebec government ... ,microbeads, Canadian Journal of Fisheries and Aquatic ... cosmetics, household cleansers, or industrial cleansers, to which ... their small size and buoyancy, they may readily ... a global contaminant in the world,s oceans, but ...
(Date:9/18/2014)... Our genetic information is stored in DNA, tiny strands ... of our bodies. To express this genetic data, our ... the instructions into proteins that perform tasks in our ... new type of RNA molecule. Unlike all other known ... RNA. Although circRNA molecules are abundant, little has been ...
(Date:9/18/2014)... disciplines will be celebrated tonight at the third annual ... the health of premature infants and in paving the ... whose work was supported by the National Science Foundation, ... Energy Commission, will be honored at a ceremony at ... group of Members of Congress will be on hand ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 23rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2
... based compounds, which are 8-mer LNA oligonucleotides, successfully inhibit ... a variety of diseases, including cancer, viral infections, cardiovascular ... affinity and target specificity of tiny LNA-based compounds enabled ... of tissues without off-target effects Tiny ...
... is a health problem that affects hundreds of ... billion every year in North America. Researchers from the ... Canada say they are gaining a deeper understanding of ... treatment using antibodies from llamas. "We have found ...
... NY) Researchers at Albert Einstein College of Medicine ... enzyme family found in humans and throughout the plant and ... Their findings suggest an entirely new strategy for treating conditions ... Sharp, Ph.D. , associate professor of physiology & biophysics ...
Cached Biology News:New data published in Nature Genetics demonstrate that tiny LNA-based compounds developed by Santaris Pharma A/S inhibit entire disease-associated microRNA families 2New data published in Nature Genetics demonstrate that tiny LNA-based compounds developed by Santaris Pharma A/S inhibit entire disease-associated microRNA families 3Researchers step closer to treatment of virulent hospital infection 2Enzyme can steer cells or possibly stop them in their tracks 2
Fast, sensitive quantitation of Mouse IgM concentration....
... 200 g of lyophilized peptide derived from ... acids 380-402; GLTPSAWEASSLRSSRHSGLSHF. This peptide ... of Cayman's EP1 receptor polyclonal antibody (Catalog ... conjunction with this antibody to block protein-antibody ...
... x 25 mm; approximately 1 mm thick, ... sections, sandblasted frosted writing ... markings will not rub off or wash off ... store at room temperature ...
Complete cell culture media with cytokines...
Biology Products: